GSK2251052
Sponsors
GlaxoSmithKline
Conditions
Community-acquired InfectionInfections, BacterialInfections, Urinary Tract
Phase 1
A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult Subjects
CompletedNCT01262885
Start: 2010-10-07End: 2011-08-25Updated: 2017-06-28
An Open-label, Randomized, Single Period, Parallel-Cohort Study To Evaluate Serum and Pulmonary Pharmacokinetics Following Single and Multiple Dose Administration of Intravenous GSK2251052 in Healthy Adult Subjects
CompletedNCT01267968
Start: 2011-01-11End: 2011-03-16Updated: 2017-07-07
A Four Part Study to Investigate Relative Bioavailability, Safety and Tolerability of up to 5 Oral Formulation of GSK2251052 in Order to Identify a Formulation for Further Evaluation in a Future Later Phase Study
TerminatedNCT01702350
Start: 2011-10-21End: 2011-12-08Updated: 2017-06-28